BOSTON, April 14, 2014 /PRNewswire/ -- PAREXEL
International (NASDAQ: PRXL), a leading global biopharmaceutical
services organization, today announced the appointment of
Peter Steiger, Ph.D., to the newly
created position of Vice President and Chief Scientific Officer for
Medical Imaging. Dr. Steiger, who has more than 25 years of
experience in the application of specialized medical imaging
techniques in support of biopharmaceutical product development,
will oversee the worldwide medical imaging scientific strategy at
PAREXEL Informatics. PAREXEL Informatics provides advanced
technology solutions to facilitate the clinical development
process.
"Peter Steiger's proven industry
track record and deep musculoskeletal imaging expertise make him an
outstanding addition to our medical imaging team," said Xavier
Flinois, President of PAREXEL Informatics. "Clinical study sponsors
increasingly rely on medical imaging technologies as surrogate
endpoints to quickly assess safety and efficacy for 'go/no-go'
pipeline decision-making. Peter's appointment reflects our ongoing
commitment to leveraging global industry expertise to advance our
client's innovative pipelines and fully support them through their
complex drug development journey."
"PAREXEL is a clear leader in the field of medical imaging in
support of clinical research, especially through the unique
combination of its in-depth therapeutic expertise and advanced
imaging technologies," said Dr. Steiger. "I am excited to work with
this renowned global team and contribute my experience to help
clients in the design and execution of their clinical studies."
Ken Faulkner, Corporate Vice
President for Medical Imaging at PAREXEL Informatics, commented,
"We are excited to welcome Dr. Steiger to our team. Under his
scientific direction, we will continue to build on our established
reputation as the premier medical imaging core laboratory in the
market."
Prior to joining PAREXEL, Dr. Steiger was the CEO of Optasia
Medical from 2006 to 2013 and CEO of Synarc from 2000 to 2005. He
also spent several years as Chief Scientist for medical imaging
device company Hologic, where he led the Medical Data Management
division responsible for supporting the use of bone densitometry
measurements in clinical studies.
A scientist by training, Dr. Steiger received his Ph.D. from the
Eidgensssische Technische Hochschule Zurich, where he researched
imaging techniques for assessing bone strength and density. He
then served as Assistant Professor in the Department of Radiology
at the University of California San
Francisco, where he was one of the pioneers in the
application of imaging endpoints to clinical trials. Dr.
Steiger has published more than 100 scientific articles and
abstracts related to medical imaging techniques. He holds
four patents in the field of musculoskeletal imaging.
PAREXEL® Informatics Medical Imaging offers
broad-ranging capabilities in the application of imaging techniques
from early clinical development through peri-approval studies. Its
experts operate globally and service a wide range of therapeutic
areas, including oncology, neurology, rheumatology, cardiology and
endocrinology.
About PAREXEL International
PAREXEL International
Corporation is a leading global biopharmaceutical services
organization, providing a broad range of knowledge-based contract
research, consulting, medical communications, and technology
solutions and services to the worldwide pharmaceutical,
biotechnology and medical device industries. Committed to providing
solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development
and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. PAREXEL
Informatics, Inc., a subsidiary of PAREXEL, provides advanced
technology solutions, including medical imaging, to facilitate the
clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 76
locations in 50 countries around the world, and has 15,100
employees. For more information about PAREXEL International
visit www.PAREXEL.com.
PAREXEL and "Your Journey. Our Mission." are trademarks or
registered trademarks of PAREXEL International Corporation or its
affiliates.
This release contains "forward-looking" statements regarding
future results and events, including, without limitation,
statements regarding expected financial results, future growth and
customer demand. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"intends," "appears," "estimates," "projects," "will," "would,"
"could," "should," "targets," and similar expressions are also
intended to identify forward-looking statements. The
forward-looking statements in this release involve a number of
risks and uncertainties. The Company's actual future results
may differ significantly from the results discussed in the
forward-looking statements contained in this release.
Important factors that might cause such a difference include, but
are not limited to, risks associated with: actual operating
performance; actual expense savings and other operating
improvements resulting from recent and anticipated restructurings;
the loss, modification, or delay of contracts which would, among
other things, adversely impact the Company's recognition of revenue
included in backlog; the Company's dependence on certain industries
and clients; the Company's ability to win new business, manage
growth and costs, and attract and retain employees; the Company's
ability to complete additional acquisitions, and to integrate newly
acquired businesses including the recent acquisitions of LIQUENT,
Inc. and HERON, Inc., or enter into new lines of business; the
impact on the Company's business of government regulation of the
drug, medical device and biotechnology industry;
consolidation within the pharmaceutical industry and competition
within the biopharmaceutical services industry; the potential for
significant liability to clients and third parties; the potential
adverse impact of health care reform; and the effects of exchange
rate fluctuations and other international economic, political, and
other risks. Such factors and others are discussed more fully
in the section entitled "Risk Factors" of the Company's Quarterly
Report on Form 10-Q for the fiscal quarter ended December 31, 2013 as filed with the SEC on
January 31, 2014, which "Risk
Factors" discussion is incorporated by reference in this press
release. The Company specifically disclaims any obligation to
update these forward-looking statements in the future. These
forward-looking statements should not be relied upon as
representing the Company's estimates or views as of any date
subsequent to the date of this press release.
Contacts:
Diana Martin,
Vice President, Corporate Communications
PAREXEL International
Tel: +1 781-434-5516
Email: Diana.Martin@PAREXEL.com
Matthew Briggs
PAN Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com
SOURCE PAREXEL International